1. P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor. (27th May 2021) Authors: Jones, J; Lee, D; Smukste, I; Cui, D; Bursavich, M G; Troast, D; Zhong, C; Wong, J E; Mangada, M M; Bain, G; Lippa, B; Ray, A S; Rogers, B N Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗